Identifying a disease and deciding to treat it are different decisions, and treating them as one is expensive.
A farmer standing in a field with a confirmed diagnosis still has to answer several questions before spending: how sure is this, how much crop is actually at risk, what will the treatment cost, and what does it save if it works. Sometimes those answers point clearly to acting. Sometimes they point to doing nothing, and that is a legitimate outcome rather than a failure of nerve.
This article is about the decision, not the agronomy. What to apply for a given condition is a question for a diagnosis and for qualified advice. When applying anything is worth it is a question of arithmetic and uncertainty, and it is the one most often skipped.
The four inputs to the decision
How certain is the identification? Treating the wrong condition costs the input and loses the time in which the actual problem progresses. A confident diagnosis and an uncertain one justify very different responses — which is why a confidence score is the most consequential figure in a diagnosis report and the one most commonly skipped past.
How much is at risk? Not the value of the whole crop — the portion this condition realistically threatens, at the stage it has reached, in the time remaining.
What does acting cost? The input, the labour, the equipment, and the time. All of it, not just the price of the chemical.
What does acting save? The loss avoided if the treatment works, discounted by the possibility that it does not.
When the third exceeds the fourth, the correct decision is not to treat — even though the disease is real and present. That is an uncomfortable conclusion and it is frequently the right one, particularly late in a season when the remaining yield no longer justifies the input.
Where the decision goes wrong
Acting on an uncertain identification. The most expensive error, because it costs the input and the delay. Where confidence is low, the cheap next step is a better photograph or a laboratory test — not a purchase.
Treating the visible rather than the significant. Some conditions look alarming and cost little; others are inconspicuous and cost a great deal. Visual severity and economic severity are different measures.
Prophylactic spraying by habit. Applying because it is that point in the season, regardless of whether the condition is present. This has real costs — input, resistance pressure over time, and beneficial organisms — that are invisible in any single season.
Ignoring the stage of the crop. The same disease at flowering and near harvest presents completely different economics. Time remaining is part of the calculation, not context around it.
Treating a whole field for a localised problem. Where a condition is confined, treating the affected area is cheaper and reduces total input.
Why the economics belong in the diagnosis
Most diagnostic tools stop at identification. The reason ARCORA reports include an economic line is that the identification alone does not settle the decision a farmer actually faces.
A report that names a condition, states how confident it is, indicates severity, and places the likely loss next to the cost of acting gives the farmer what the decision requires. A report that names the condition and recommends a treatment implicitly assumes the treatment is always worth it — which is not true, and the person carrying the cost is entitled to see both.
The scale this operates against is substantial: the losses Indian farmers absorb to crop disease run to enormous figures, and a meaningful share of what is spent goes on treatments applied to the wrong problem, or applied when the economics never justified it. Reducing the second category costs nothing but better information.
Timing changes the arithmetic
Speed matters in crop diagnosis for a reason specific to this decision: the window in which treatment is effective is frequently short, and it closes while a sample travels to a laboratory or an advisor becomes available.
That produces a practical asymmetry. Early in the window, a moderately confident diagnosis may justify acting, because delay to confirm risks losing the opportunity entirely. Late in the window, even a confident diagnosis may not justify acting, because the damage is largely done.
The same information supports opposite decisions depending on when it arrives. This is why diagnostic speed is a clinical variable rather than a convenience — a point covered in the ARCORA design.
What the system will not tell you
Being clear about limits.
It does not know your budget. A decision that is marginal on paper may be impossible in practice, and that is a legitimate constraint rather than a mistake.
It does not know local conditions perfectly. Weather, water availability and what neighbouring fields are doing all affect outcomes.
Some identifications cannot be made from an image. Certain soil-borne pathogens and deficiencies that mimic disease need laboratory work. Where a report issues a lab referral, that is the boundary of the method being stated honestly rather than a gap.
It does not replace an agronomist. It resolves the common, well-evidenced cases quickly and cheaply, and identifies which cases need a person.
Frequently asked questions
If a disease is confirmed, why would I not treat it?
Because treatment costs money and does not always save more than it costs — particularly late in a season, on a lower-value crop, or where the affected portion is small. The right question is not whether disease is present but whether acting improves the outcome net of cost.
What should I do if confidence is low?
Photograph again properly before spending: the affected area, an unaffected area for comparison, and any other plant part showing change. Low confidence usually reflects limited visual evidence rather than an unusual condition.
Is it cheaper to treat preventively?
Sometimes, for specific conditions in specific seasons. As a general habit it is expensive — inputs applied whether or not needed, with resistance pressure accumulating over years.
How do I judge how much crop is at risk?
Stage of the crop, proportion affected, and how quickly the condition spreads under current conditions. Severity ratings exist to support this judgement rather than replace it.
Who do I ask if the decision is still unclear?
Your FPO is usually the right route — several maintain relationships with agricultural universities and KVKs, which is also where a lab referral gets actioned. How FPOs build shared diagnostic knowledge covers why that institutional route matters.
Where to start
Before the next application, answer four questions in order: how confident is the identification, how much is genuinely at risk, what will this cost in full, and what does it save if it works.
If the first answer is weak, get a better diagnosis before spending. If the third exceeds the fourth, the disciplined decision is to accept the loss — and that decision is easier to make with the numbers in front of you than in the field under pressure.
To discuss deploying ARCORA through an FPO, get in touch.